Is Elevance Health Stock Outperforming the Nasdaq?

Core Insights - Elevance Health, Inc. operates as a health benefits company with a market cap of $74.7 billion, supporting consumers and communities throughout their healthcare journey [1][2] Company Overview - Elevance employs over 100,000 associates and serves millions, addressing a full range of health needs through an integrated approach and a digital health platform [2] Stock Performance - Elevance's stock has dropped 26.2% from its 52-week high of $458.75 on April 8, but has gained 9.2% over the past three months, outperforming the Nasdaq Composite's 7.8% gains during the same period [3] - Year-to-date, Elevance's stock has declined 8.2% and 15.8% over the past 52 weeks, while the Nasdaq has surged 20.2% in 2025 and 21.1% over the past year [4] Financial Results - Despite better-than-expected Q3 results, Elevance's stock dropped 1.2% following the earnings release on October 21. The company reported a 12% year-over-year increase in topline revenue to $50 billion, exceeding expectations by 1.2% [5] - Adjusted EPS for the quarter was $6.03, a 29.9% year-over-year decline, but surpassed consensus estimates by 21.1% [5] Peer Comparison - Elevance has underperformed compared to The Cigna Group, which saw a marginal 80 basis points increase year-to-date, but performed slightly better than Cigna's 16.9% drop over the past 52 weeks [6]